Skip to main content
Year archive

Abliva — 2019 filings

All 45 regulatory filings released by Abliva (ABLI) in 2019, sourced directly from the official regulator.

45 Filings
2019 Period
2019 filings (45)
Filing Released Lang
NeuroVive announces settlement in dispute with CicloMulsion AG
Regulatory Filings
2019-12-16 English
NeuroVive meddelar förlikning i tvist med CicloMulsion AG
Legal Proceedings Report
2019-12-16 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Q3 2019
2019-11-20 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report 9M 2019
2019-11-20 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-10-04 English
Interim / Quarterly Report 2019
Interim / Quarterly Report Q2 2019
2019-08-21 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report H1 2019
2019-08-21 English
NeuroVive’s NeuroSTAT project receives FDA Fast Track designation
Regulatory Filings
2019-07-27 English
NeuroVives NeuroSTAT-projekt får Fast Track-status från FDA
Regulatory Filings
2019-07-27 Swedish
NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study
Regulatory Filings
2019-07-04 English
NeuroVive inleder den andra delen av sin pågående kliniska fas Ia/b-studie med KL1333
Regulatory Filings
2019-07-04 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Q1 2019
2019-05-21 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Q1 2019
2019-05-21 English
NeuroVives IND för klinisk utveckling av NeuroSTAT godkänd av FDA
Regulatory Filings
2019-05-10 Swedish
NeuroVive’s IND for clinical development of NeuroSTAT approved by FDA
Regulatory Filings
2019-05-10 English
NeuroVive announces ruling from Supreme Court in case between the company and CicloMulsion AG
Legal Proceedings Report
2019-04-30 English
NeuroVive meddelar dom från Högsta domstolen i mål mellan bolaget och CicloMulsion AG
Legal Proceedings Report
2019-04-30 Swedish
Resolutions from Annual General Meeting in NeuroVive Pharmaceutical AB (publ)
AGM Information
2019-04-25 English
Beslut vid årsstämma i NeuroVive Pharmaceutical AB (publ)
AGM Information
2019-04-25 Swedish
Amended number of shares and votes in NeuroVive Pharmaceutical AB (publ)
Share Issue/Capital Change
2019-03-29 English
Ändring av antal aktier och röster i NeuroVive Pharmaceutical AB (publ)
Share Issue/Capital Change
2019-03-29 Swedish
Annual Report 2018
Annual Report FY 2018
2019-03-25 Swedish
Annual Report 2018
Annual Report FY 2018
2019-03-25 English
Notice of Annual General Meeting of Shareholders in NeuroVive Pharmaceutical AB (publ)
AGM Information
2019-03-25 English
Kallelse till årsstämma i NeuroVive Pharmaceutical AB (publ)
AGM Information
2019-03-25 Swedish
NeuroVive enrolls first subject in its KL1333 phase Ia/b clinical study
Regulatory Filings
2019-03-19 English
NeuroVive rekryterar den första försökspersonen till sin kliniska fas Ia/b-studie med KL1333
Regulatory Filings
2019-03-19 Swedish
Major Shareholding Notification 2019
Major Shareholding Notification
2019-03-11 English
NeuroVive receives SEK 28.2 Million in a directed new share issue
Capital/Financing Update
2019-03-07 English
NeuroVive erhåller 28,2 miljoner SEK i en riktad nyemission
Share Issue/Capital Change
2019-03-07 Swedish
Major Shareholding Notification 2019
Major Shareholding Notification
2019-03-01 English
Amended number of shares and votes in NeuroVive Pharmaceutical AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2019-02-28 English
Ändring av antal aktier och röster i NeuroVive Pharmaceutical AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2019-02-28 Swedish
Earnings Release 2018
Earnings Release FY 2018
2019-02-28 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report FY 2018
2019-02-28 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-02-26 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-02-22 English
NeuroVive tillförs cirka 99 MSEK i emissionslikvid
Share Issue/Capital Change
2019-02-11 Swedish
NeuroVive is supplied with approximately MSEK 99.0 in share issue proceeds
Capital/Financing Update
2019-02-11 English
NeuroVives styrelse, ledning och medarbetare tecknar aktier i pågående företrädesemission
Share Issue/Capital Change
2019-01-25 Swedish
NeuroVive’s Board Members, Senior Executives and employees have subscribed to shares in the ongoing rights issue
Share Issue/Capital Change
2019-01-25 English
NeuroVive publishes prospectus in connection with preferential rights issue
Capital/Financing Update
2019-01-22 English
NeuroVive offentliggör prospekt med anledning av företrädesemission
Capital/Financing Update
2019-01-22 Swedish
NeuroVive Pharmaceutical AB (publ): report from EGM
AGM Information
2019-01-17 English
NeuroVive Pharmaceutical AB (publ): kommuniké från extra bolagsstämma
AGM Information
2019-01-17 Swedish